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Abstract
Objective This study assessed the potential operational
feasibility and acceptability of a heat-stable, inhaled
oxytocin (IOT) product for community-based prevention of
postpartum haemorrhage in Myanmar.
Methods A qualitative inquiry was conducted between
June 2015 and February 2016 through focus group
discussions and in-depth interviews. Research was
conducted in South Dagon township (urban setting) and in
Ngape and Thanlyin townships (rural settings) in Myanmar.
Eleven focus group discussions and 16 in-depth interviews
were conducted with mothers, healthcare providers and
other key informants. All audio recordings were transcribed
verbatim in Myanmar language and were translated into
English. Thematic content analysis was done using NVivo
software.
Results Future introduction of an IOT product for
community-based services was found to be acceptable
among mothers and healthcare providers and would be
feasible for use by lower cadres of healthcare providers,
even in remote settings. Responses from healthcare
providers and community members highlighted that
midwives and volunteer auxiliary midwives would be
key advocates for promoting community acceptance of
the product. Healthcare providers perceived the ease
of use and lack of dependence on cold storage as the
main enablers for IOT compared with the current gold
standard oxytocin injection. A single-use disposable
device with clear pictorial instructions and a price that
would be affordable by the poorest communities was
suggested. Appropriate training was also said to be
essential for the future induction of the product into
community settings.
Conclusion In Myanmar, where home births are common,
access to cold storage and skilled personnel who are able
to deliver injectable oxytocin is limited. Among community
members and healthcare providers, IOT was perceived
to be an acceptable and feasible intervention for use by
lower cadres of healthcare workers, and thus may be
an alternative solution for the prevention of postpartum
haemorrhage in community-based settings in the future.

Strengths and limitations of this study
►► This is the first qualitative inquiry exploring the

operational feasibility and acceptability of a future
heat-stable, inhaled oxytocin (IOT) product for community-based prevention of postpartum haemorrhage in Myanmar to inform product development.
►► The participants involved healthcare workers and
stakeholders from various levels of the healthcare
system and the community and from both urban and
rural areas to provide an insight into a range of different perspectives, which has been triangulated to
enrich the findings.
►► Since the study was conducted in selected townships of Myanmar, the views and opinions towards
IOT product may differ in other places of the country.
►► Operational feasibility and acceptability of the IOT
product was assessed with a similar drug delivery
device but in the absence of the final product and
in the context of limited experience with inhalable
medications, which could have attributed to overwhelmingly positive perspectives.

Background
Postpartum haemorrhage (PPH) is the
leading cause of maternal mortality worldwide, contributing to approximately 20% of
total maternal deaths.1 The gold standard
uterotonic agent, oxytocin, has been shown
to reduce the risk of PPH by 50% and is
recommended by the WHO for administration via intravenous or intramuscular injection to every woman during the third stage of
labour for the prevention of PPH.2 3
Several factors currently limit widespread
access to oxytocin in developing countries
where the majority of PPH deaths occur.4
In the injectable form, oxytocin is sensitive
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maternal mortality is PPH, which is estimated to account
for 30% of maternal deaths.18 Approximately 70% of
the population resides in rural areas and the majority
of the childbirths occur at home.19 The health system in
Myanmar is divided into central-level, state/division-level
and township-level services. At the township level, healthcare services are provided through a township hospital,
station hospital, rural health centres and subrural health
centres. A township medical officer is responsible for
administrative and clinical decision making. Maternal
and child health services at the subcentre and community-level are provided by a midwife (MW). Due to shortages
in MWs, a volunteer cadre of auxiliary midwives (AMWs)
at the community-level support the MWs with provision
of maternal and child health services, including care for
uncomplicated deliveries.
Approximately one-third of all deliveries in Myanmar
are attended out-of-facility settings by an MW or AMW.20
However, these providers have limited capacity to actively
manage the third stage of labour.21 22 Government policy
prohibits MWs and AMWs from delivering injections
outside of the health facility setting and thus currently
MWs (but not AMWs) are authorised to use misoprostol
for routine prevention of PPH and can only deliver an
injection of oxytocin for ‘life-saving’ purposes. AMWs
face further restrictions and are generally not authorised
to use any medications to manage childbirth or PPH.21 In
the absence of national policy allowing these providers to
use injectable oxytocin, access to gold standard measures
for the prevention of PPH is limited.21 Furthermore, the
ability of MWs and AMWs to maintain a consistent cold
chain for oxytocin is severely limited as most rural health
centres or subcentres are not equipped with cold storage
facilities.23 Thus, out-of-facility deliveries attended by
MWs or AMWs represent a setting where IOT could be
beneficial through expanding access to first-line therapy
and obviating the need for cold storage.
To guide product development and implementation
planning activities, this study assessed the operational
feasibility and acceptability of IOT for improving community-based care in Myanmar.

Methods
A qualitative inquiry using focus group discussions and
in-depth interviews was conducted to gain insight into
the perspectives of healthcare providers, community
members and key informants. Methods are reported
according to the Consolidated Criteria for Reporting
Qualitative Research checklist.24
Study setting and participants
Three administrative areas in Myanmar, South Dagon,
Ngape and Thanlyin townships, were purposively selected
for the study, based on their geographic location (rural/
urban) and extent of use of the AMW cadre, and after
discussion with Ministry of Health officials. South Dagon
is an urban township and has a population of 297 000 with
Than KK, et al. BMJ Open 2018;8:e022140. doi:10.1136/bmjopen-2018-022140
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to heat and must be supplied and stored under cool or
cold conditions in order to maintain drug potency.5 6 This
presents a significant problem particularly in rural areas
where the availability of cold chain storage is limited.
The necessity to administer oxytocin via an injection
further limits widespread access to this intervention. In
low-income and middle-income countries, a significant
proportion of births occur outside healthcare facilities,
in the absence of the equipment and medical personnel
required to deliver an injection.7–9
An alternative to injectable oxytocin is misoprostol. This
is a heat-stable oral drug, which has been recommended
by WHO in settings where injectable oxytocin is not available. However, it is less effective with more frequent side
effects compared with oxytocin, and thus the WHO recommends that availability of misoprostol should not detract
from efforts to make oxytocin universally accessible.2 10 In
addition, uptake of misoprostol has faced significant challenges in some territories due to policymakers’ concerns
around abortion misuse and reluctance for task-shifting
of uterotonics to community-based healthcare providers
who have been the primary target for many misoprostol
implementation programmes.11 12
Therefore, Monash University and GlaxoSmithKline
are currently collaborating to develop a heat-stable, easyto-use, low-cost, dry powder oxytocin product for respiratory delivery to prevent PPH in resource-constrained
settings.13 14 The product is being designed to simplify the
administration of oxytocin and remove the need for refrigerated storage or additional consumables for administration. Inhaled oxytocin (IOT) therefore has the potential
to extend on the value proposition of misoprostol by
providing the gold standard uterotonic in a format that is
suitable for use in settings where access to a reliable cold
chain or skilled birth attendant is limited. The development of the IOT product is currently at an early clinical
trials stage with pharmacokinetic data in non-pregnant
female volunteers indicating that comparable systemic
exposure of oxytocin with that achieved following a 10 IU
intramuscular injection can be delivered through inhaled
delivery.14 While these data indicate that an inhaled
product has the potential to be similarly effective to the
current injection, further clinical trials are required and
will be conducted to characterise the product fully and
determine utility in low-resource settings. However, there
are many examples of promising global health technologies that have failed to achieve significant uptake
and impact, despite possessing the technical attributes
required to address an unmet need.15 16 Thus, in addition to clinical efficacy, consideration must be given to
the end-user acceptability and feasibility of product use,
as these will be equally important drivers of the ability of
IOT to deliver impact in target territories.
Myanmar represents a territory where the IOT product
has the potential to improve maternal health outcomes.
The country has one of the highest maternal mortality
ratios in the Southeast Asian region at 282 maternal
deaths per 100 000 live births.17 The main cause of
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Research team and data collection
The research team was led by an experienced qualitative Myanmar researcher. All six team members (three
were medical doctors and the others had worked in the
medical field) had previous experience with qualitative
data collection. Apart from one, all were women. A 4-day
training was given to all researchers on background,
objectives and design of the study, and data collection,
management and analysis methods. None of the research
team members had a prior relationship with study participants. Rapport with the participants was built during
focus group discussion through self-introduction and
explaining the research objectives.
Data collection for in-depth interviews was mostly
conducted in the participants’ office as the place of
choice by the interviewee ensuring confidentiality and
convenience. Focus group discussions with MWs, AMWs
and mothers were conducted in comfortable private
places where confidentiality and privacy were ensured.
Separate FGDs were conducted for different categories
of participants. Question guides were used to investigate the practices around childbirth, beliefs around
PPH and bleeding, perspectives of medications around
the time of birth, oxytocin current practices, perspective
towards IOT and possible implementation strategies. In
Than KK, et al. BMJ Open 2018;8:e022140. doi:10.1136/bmjopen-2018-022140

all interviews and focus groups, only after the discussion
moved towards management of PPH, the moderator gave
a brief description of IOT. To aid in the description of the
product, a Rotahaler device was shown as an example of
a low-cost, passive inhaler, which could be used for inhalable oxytocin.
The duration of the focus groups and interviews ranged
from 30 min to 90 min, and most were conducted in
Myanmar language. Data were collected until it was felt
that data saturation was obtained. All the focus group
discussions were audio-recorded using a digital recorder.
For the in-depth interviews, apart from three obstetricians and two key informants from the pharmaceutical
industry who declined to be digitally recorded, all others
were digitally recorded. Contemporaneous notes were
taken for all discussions and interviews.
Data management and analysis
All Myanmar language interviews and focus group discussions were transcribed in Myanmar language by the note
taker for the focus group discussions and by the interviewer for the in-depth interviews and were checked
against the notes for consistency and validity. Transcripts
were translated into English by a translator and checked
against the Myanmar transcripts to ensure the quality and
the meaning of the original transcripts was not lost. To
aid the analysis, NVivo (V.11, VMWare) software was used.
Three data analysts coded the transcripts. Reliability
coding was set at 80% agreement, and the inter-coder reliability was found to be over 80%. This approach balanced
the differing views of the researchers in the study. Participant characteristic codes (obstetricians, hospital staff,
MWs, AMWs and mothers) and setting codes (urban and
rural) were also considered during the coding process.
Before finalising the code structure, all the researchers
who coded the transcripts collaboratively reviewed and
agreed on the final structure. Qualitative content analysis
using both inductive and deductive approaches was used
in interpreting the findings.
Patient and public involvement
This study sought to understand the perceptions of
community members, healthcare providers and key informants towards the conceptual acceptability and feasibility
of an IOT product for the prevention of PPH in community settings of Myanmar. No intervention was tested as
part of this research, and the participants are not formally
considered ‘patients’ in that they are not seeking or
receiving medical care as part of this study.
However, the research described here is in itself a
strategy to increase patient and public involvement in
research. Through the conduct of this study, the product
development team has created a mechanism by which the
design and future implementation of the IOT product
can be informed by the priorities, experiences and preferences of the target population for the product (ie,
mothers and healthcare providers).
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one 50-bed township hospital, one station hospital and
two urban health centres. Thanlyin is a large township,
which has both urban and rural characteristics and has
a population of 188 000 with a 150-bed district hospital,
one station hospital and five rural health centres. Ngape
is a rural township and has a population of 46 500 and
has one 25-bed township hospital, one station hospital,
two rural health centres and 14 subcentres. South Dagon
and Thanlyin are located in Yangon region, where an
average of 94.6% of women engage a skilled provider
(including an MW) for antenatal care and the average
number of visits is approximately four.22 25 While only
65.4% of women give birth in a health facility, coverage of
skilled attendance at birth is 82.5%.22 Ngape is situated in
Magway region, where 82.5% of women engage a skilled
provider for antenatal care and the average number of
visits is four.22 25 Only 37.5% give birth in a health facility,
however, 68.4% engage a skilled provider and a further
6.8% of deliveries are attended at home by an AMW.22
A total of 16 in-depth interviews and 11 focus group
discussions were conducted involving 100 persons. Focus
groups had between 5 and 10 participants and included
a total of 26 MWs, 28 AMWs and 30 mothers with a child
aged less than 3 years. In-depth interviews consisted of
healthcare providers at the township level, obstetricians
from both the public and private healthcare system and
other key informants from the pharmaceutical industry
and agencies working on maternal and child health. Key
informants were selected on the basis of their knowledge
and experience with the local health system and thus
could provide insights into the considerations for new
product introduction.

Open access

Ethics
Written informed consent was obtained from all participants, all of whom were reimbursed for the actual cost
of travel plus a daily allowance to cover meal costs (3000
kyats, equivalent to US$2.5).

Findings
Current perceptions and practices towards PPH in community
settings
Cultural beliefs towards postpartum bleeding
Regardless of the place of residence, many women in the
study preferred home births over facility births, mainly
because of cost, the supportive family environment and
inconvenience of engaging a facility. Women in the study
described postpartum blood as ‘bad’ or ‘impure’ and
explained that it was essential to remove this blood from
the body in order to avoid subsequent pain or hardship.
This viewpoint seemed more common among participants
from rural areas as compared with their urban counterparts. A traditional oral medicine named ‘Memakin say’
was commonly used in the first 3 days after delivery to
facilitate bleeding and clean the body.
You see, we have to carry the pregnancy for 9 to 10
months and the bad blood accumulated in our body
for so long. So with the birth of the baby, it should
all come out… or else if it stays in our body, we will
not be healthy. So bleeding is a necessity for us after
delivery. If it does not come out…. pain in supra-pubic area will occur. (33-year-old mother of three, rural
area)
Despite traditional beliefs surrounding postpartum
bleeding, a prominent theme during discussions with
mothers was the trust placed in the formal health sector
for matters relating to maternal health. In general, rural
participants saw community-based providers, such as
MWs and AMWs, as the key decision makers or advisers
for health, whereas participants from urban areas seemed
to place more reliance on staff at healthcare facilities. For
the majority of women in the study, MWs and AMWs were
the main home birth attendants with occasional births
attended by traditional birth attendants.
Burden of PPH, its management and associated challenges
Alongside the perception of the need to expel bad blood,
excessive blood loss after childbirth was also cited as a
danger by many community members and two mothers
participating in the study had personally experienced
excessive bleeding postpartum.
4

We are afraid sometimes that after the birth of the
baby, bleeding might occur. (33-year-old mother of
four, rural area)
Mothers who had seen postpartum bleeding explained
that dangerous levels of bleeding were recognised by
monitoring how quickly a sarong (a traditional wrapped
skirt for women) became soaked with blood. While many
healthcare providers suggested that PPH is rare, others
spoke of the serious nature of the condition and described
excessive bleeding like a ‘pipe water falling from a pipeline’. AMWs often described the challenges associated
with PPH management in the context of their restricted
authority to administer medications and their reliance on
MWs who were often not readily accessible.
I know bleeding is serious and the mother can die,
but what shall we do apart from waiting. It was so long
waiting for her (the MW) to arrive. I dare not to give
injection. I am afraid of someone seeing me giving an
injection to the patient. (AMW, rural area)
Another challenge faced by community-based home
birth care providers is the law restricted towards injection.
Healthcare providers explained that the current narcotic
law in Myanmar restricts use of injections by MWs and
AMWs such that they are prohibited from routinely
delivering an oxytocin injection for the prevention of
PPH when attending out-of-facility deliveries. However,
in practice, some MWs are administering an injection of
oxytocin with authorisation from the residing township
medical officers due to the live-saving potential of the
drug. In practice, the absence of national law authorising both MWs and AMWs to deliver injectable oxytocin
restricts widespread use of oxytocin for PPH prevention.
Another problem is that in our country, the narcotics
laws do not allow the midwives to give (medicines in)
injection form. So if we can avoid the injection form,
and then we can use it (oxytocin)…and then it is definitely useful for prevention of PPH. (Obstetrician in
private practice, urban area)
Access to quality oxytocin in community settings
Prevention and management of PPH was mainly
performed by MW at the community level in which injection oxytocin was used. However, reliability and availability of the cold storage required to maintain oxytocin
quality within the settings of community-based care was
limited. Refrigerators were not available at rural health
centres and subcentres, which are designed as the bases
for community-based MWs. Community-based providers
can keep items cold for short periods using ice bricks
(supplied from the nearest township hospital) in vaccine
transport carriers, but they explained the difficulty they
would face if they were to maintain consistent refrigeration for oxytocin.
We have to buy the ice in the city and there must
be electricity to keep it cool. In the rainy season, it
Than KK, et al. BMJ Open 2018;8:e022140. doi:10.1136/bmjopen-2018-022140
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While the design, recruitment and conduct of this study
was not directly informed by members of the public who
represent the participant groups involved, findings from
the study were disseminated back to the public through
the conduct of a half day workshop in March 2017, which
was attended by healthcare providers, government officials and members of the pharmaceutical industry.
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In settings where cold storage facilities are available,
unreliability of electricity supply was cited as a barrier,
with frequent power outages and voltage fluctuation.
Since most of the injection oxytocin were not kept in a
cold storage, which may have effect on the quality.
Acceptability and feasibility of IOT
Conceptual acceptability
Acceptability was explored through the perceived need
for and willingness to use the IOT product when available. Although general acceptance of all forms of medication prescribed by healthcare providers was high among
the community, injections stood out to be most preferred
due to their perceived rapid action. Positive views towards
inhalers were also expressed by community members,
who cited ease of use and a believed rapid onset of action
as benefits. One woman saw the inhalant as a less painful
alternative to injections.
We don’t need to drink it and it does not hurt
like an injection, I think the inhaler will be really
good. (23-year-old mother, urban area)
A key informant from the pharmaceutical industry
expressed concerns about the acceptability of the IOT
product to community members, as past introduction
of a dry powder inhaler for asthma had failed to result
in sustainable uptake in Myanmar. This informant speculated that this was due to patients’ concern about
inhaling powder into the lungs. However, this concern
was not heard from community members participating in
this study and most mothers expressed their willingness
to accept IOT compared with oral and injectable drugs.
Some concerns were expressed by a minority of these
stakeholders, most commonly, they worried whether they
would know the correct time at which to use the drug,
fearing that they would inhale too early (before the baby
is delivered).
Mothers and healthcare providers alike expressed a
strong desire for a single-use device packaged within
a sealed sachet to keep it ‘sterile’ and to prevent transmission of infections. Although there was no preference to the colour, the smell of the drug was thought to
have a significant impact on acceptability. Several MWs
and AMWs and one obstetrician suggested that mothers
would be reluctant to inhale the drug if it has a strong
or unpleasant odour. However, there were some mothers
who explained that while a ‘soft’ smell would be favoured,
they would be willing and able to inhale the IOT product
regardless, if it was important for their health.
Some MWs and AMWs held concerns about the feasibility of a mother inhaling from a device immediately
after delivery, fearing the woman may be too tired. They
suggested that only one inhalation or potentially a few
with not too much force would be feasible for postpartum
women. Other healthcare providers disputed this idea
Than KK, et al. BMJ Open 2018;8:e022140. doi:10.1136/bmjopen-2018-022140

and suggested that mothers would be completely able to
use the inhaler as shown. This viewpoint was supported
by mothers themselves, many of whom declared that they
would have no problem using the device after delivery.
Following a demonstration of the Rotahaler device
during the interviews and focus groups, both community
members and healthcare providers remarked on the ease
of use of the inhaler.
This ease of administration was highlighted as a benefit
of the IOT product for MWs and AMWs attending home
births, who are often alone and struggle to manage all
aspects of maternal and neonatal care that are required
during the early postpartum period.
Actually, that (IOT) is more comfortable. It also reduces work. The injection to the butt will be like:
open it, put it and such. This will be like open and can
just say to the patient to inhale it by herself. (AMW,
urban area)
Healthcare providers, especially the obstetricians,
emphasised that the product should first be demonstrated to be effective with few side effects before it would
be accepted by either themselves or the community. They
suggested that assurance of safety and efficacy could
come from WHO recommendations or from proven clinical trials before introduction of the product into routine
clinical care.
Although I think IOT is useful, the best thing is to
wait for the WHO package. They will have some trials
and then they will find out the potency and efficacy
and then safety and then after that they will recommend to use in developing countries. (Obstetrician
in private practice, urban area)
Administration of IOT
MWs and AMWs attending home births were suggested
as suitable providers for the introduction of IOT. MWs
were seen as possessing the skills and knowledge required
for them to safely and effectively administer the drug or
instruct the mother or a relative to do so. The ease of use
of the IOT product was also thought to offer the potential to relieve the burden on MWs as they are often alone
when attending deliveries in the community.
MW 4: ‘We can do our management better [with
IOT] during birth’.
MW 9: ‘ … [W]e can ask someone to help us give the
inhalation to the mother, but we cannot do this with
an injection as it needs a healthcare provider with
skill to do it’. (FGD with MWs, urban area)
Opinions towards task-shifting IOT administration to
AMWs were mixed among healthcare providers. In hardto-reach areas, AMWs, who often reside in the remote
villages, were suggested as a more accessible provider of
essential care in the absence of an MW. Some MWs and
obstetricians were in support of IOT use by AMWs and
5

BMJ Open: first published as 10.1136/bmjopen-2018-022140 on 24 October 2018. Downloaded from http://bmjopen.bmj.com/ on November 5, 2020 by guest. Protected by copyright.

[keeping oxytocin cold] would not be feasible. (MW,
rural area)
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I think it should be in the hands of AMW, especially
in the hilly regions. In emergency situations mothers
don’t have anyone to rely on. (MW, rural area)
MWs themselves explained that they often attend deliveries in the absence of an MW, and in this situation, a
non-injectable medication, such as IOT, would provide
them the opportunity to protect the mother from a
potentially fatal PPH.
Conversely, some of the township-level providers and
MWs expressed their concern about the possibility of
AMWs misusing IOT during delivery to augment labour,
a practice suggested to be common among AMWs in the
past. However, there were also suggestions that release of
IOT with clear instructions and rebranding as a product
indicated for postpartum use only (unlike the injection),
could benefit women and community-based providers.
One AMW suggested that the perception of oxytocin as a
drug for augmenting labour is associated specifically with
the injection and so may not be automatically applied to
the inhaler.
Moderator: ‘Do people consider it [IOT] as a uterus
opening drug?’.
AMW: ‘They think injection will open the uterus, not
an inhaler, so I think it is ok’. (FGD with AMWs, rural
area)
Regarding community distribution of IOT to mothers,
the responses varied widely between the community and
the healthcare providers. Mothers supported the idea,
explaining that it would ensure they have the product
regardless of where they deliver and who attends them.
It would be more convenient if you can give it to the
mothers, then we won’t need to worry about getting
the drug in time. Even if the Sayarma (MW) did not
arrive in time, we can still use it after the delivery of
the baby. It would be really useful. (28-year-old mother of three, rural area)
In contrast, healthcare providers were more opposed
to community distribution of IOT due to the fact that
mothers may use the product before labour or delivery.
Some mothers and healthcare providers suggested that
community distribution of IOT should be selective and
targeted specifically to mothers in hard-to-reach areas, as
they are most likely to be at risk of delivering outside a
facility or in the absence of a skilled provider. In general,
a prominent opinion among community members and
healthcare providers was that particular care was needed
for community distribution of IOT.
Training
While there was some awareness of orally inhaled medicines among community members, none of the mothers
participating in this study had personally used an oral
inhaler. As such, all stakeholders stressed the importance
6

of training mothers how to use the inhaler. All participants
suggested that training for mothers on IOT should start
during the antenatal period. They emphasised that early
exposure to the device would be beneficial for mothers to
understand its function and intended use. The local MW
of each village was suggested as the most suitable person
for training the mother.
For the training of healthcare providers, suggestions centred on the necessity to conduct systematic
training to ensure all cadres of healthcare providers
are adequately educated about the IOT product. In the
current model, healthcare workers are trained through
a cascade system, beginning with a training of trainers
workshop at the national level and thereafter through
states/regions, districts, townships and finally down to
the community-level health workers. However, some MWs
complained that this mechanism of training can result in
messages being inaccurately or ineffectively passed down
through the chain. Several MWs suggested that direct
training where they can interact with teachers at the
central level would be preferable to them. Additionally,
a trainer at national level explained that the feasibility
of conducting coordinated nationwide training would
depend on finances and supplies. The suggested training
content included indication for use, contraindications,
side effects, possibility of repeated dose and storage
requirements.
Clear instructions on the purpose of the drug, how to
use the device and possible side effects either written in
Myanmar language or pictorially depicted were suggested
by some mothers and healthcare providers.
IOT pricing
Reports from mothers and healthcare providers participating in this study suggested that in recent years, drugs
and services are provided free of charge for women delivering in healthcare facilities. For out-of-facility deliveries
attended by MWs, many of the respondents in the study
mentioned that women pay for delivery with cash or gifts
but that drugs such as oxytocin are not purchased directly
by patients. This suggests that patients’ out-of-pocket expenditure for oxytocin is currently minimal, and therefore,
IOT may likewise be provided free of charge to end-users.
However, some healthcare providers expressed concerns
over the sustainability of current levels of government
health financing, and thus, the possibility that user charges
will be applied to IOT should be considered. As such,
participants were asked to suggest a price for IOT to ensure
its affordability in the event that patients are required to
directly purchase the product. Most stakeholders felt that
a price between 500 and 1000 kyats (US$0.40–US$0.80)
would be most affordable to community members and that
not more than 500 kyats (US$0.40) would be necessary to
also ensure affordability to low-income families.
Discussion
To understand the acceptability and feasibility of implementing IOT in Myanmar, a situation assessment was
Than KK, et al. BMJ Open 2018;8:e022140. doi:10.1136/bmjopen-2018-022140
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suggested that, particularly in remote areas, it would be
necessary to allow AMWs direct access to the product.
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In addition to the safety and efficacy of the product,
a common concern among healthcare providers was
whether the device could be operated correctly to deliver
the required dose to the patient. In this regard, care will
need to be taken to ensure that community members can
be appropriately trained on how to use the device given
that the utility of the IOT product may to some degree be
dependent on their participation in drug administration.
Given that home births remain common in Myanmar,
we explored the acceptability of IOT use in these settings,
with particular consideration for the possibility of product
use by MW or AMW, who are the common attendants of
out-of-facility deliveries. Most stakeholders suggested that
IOT would be both appropriate and beneficial for use
by MWs at out-of-facility deliveries. Healthcare providers
suggested that MWs possessed the skills and knowledge
required to administer the drug or instruct the mother
or relative on administration. At a policy level, a non-injectable form of oxytocin aligns with both national
drug law (which prohibits MWs use of injections) and
standard treatment guidelines (which prioritise use of
oxytocin over misoprostol for prevention of PPH). Attitudes towards the acceptability of product use by AMW
were more varied. Although current policy states that
AMWs are only to assist MWs, staff shortages and extreme
geographic barriers severely limit accessibility of MWs,
and as a result, AMWs are often required to act as the
sole attendant for out-of-facility deliveries in rural remote
areas.21 26 However, national policy currently prohibits use
of uterotonics by AMWs, and many stakeholders participating in this study had reservations about tasking-shifting
IOT to these providers.27 Objections were primarily based
on fears that the drug would be misused for the induction
or augmentation of labour, which was reported to be a
common practice among AMWs in the past. In contrast,
there were some stakeholders, including township-level
policymakers, who suggested that the knowledge and
skill set of AMWs is improving over time and that these
providers should be considered for IOT administration.
Training for end-users can be considered in the context of
training healthcare providers and community members
in the use of IOT. The coordinated chain of training
down the hierarchy of healthcare providers currently in
place in Myanmar was described as a means to efficiently
and effectively ensure all healthcare providers in the
country receive appropriate training. However, assuring
the consistency of these trainings may be a challenge and
may require both financial and system support.
Training pregnant women and their families through
antenatal care appears to be highly feasible as coverage
of at least one antenatal visit among women in Myanmar
is high (81%).22 However, given the expressed unfamiliarity of community members towards inhalers, repeated
trainings may be necessary. Compared with one antenatal
visit, attendance of at least four sessions is less common,
particularly in rural areas where 51% of women attend
at least four visits, compared with 84% of their urban
counterparts.22 Thus, mechanisms to ensure adequate
7
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conducted to explore current attitudes and practices
towards childbirth, PPH and oxytocin. IOT acceptability
was explored from the point of view of community
members and healthcare providers, while perspectives
of all stakeholders were used to understand the operational feasibility. Responses to the IOT product were
overwhelmingly positive from community members, all
of whom expressed an unconditional acceptance of the
product and praised its ease of use. These expressions
of acceptance may in part be due to an appreciation for
a product that replaces an injection, as the fear of pain
associated with injectable products was a concern for
some community members. Additionally, community
members who were familiar with inhalers generally held
positive views towards this route of administration, due
to the rapid relief that is experienced after use of these
medications for respiratory conditions (such as asthma).
However, there may also be an element of social desirability bias in participant responses, and acceptability
of the product to community members should be critically evaluated. For example, a barrier to the acceptability of IOT may arise from existing traditional beliefs
and practices, which encourage expulsion of blood after
childbirth. Community members may therefore resist a
product that controls or reduces postpartum blood loss.
However, many mothers from both urban and rural areas
expressed concerns about excessive bleeding after childbirth, attitudes that could be harnessed to facilitate acceptance of IOT as a product for preventing dangerous levels
of bleeding. Furthermore, community members predominantly place their trust in the healthcare system, particularly in MWs. Thus, it is likely that advice from MWs and
other healthcare providers will dispel potentially inhibiting attitudes and facilitate community acceptance of
IOT. These findings will help inform the design of education strategies in order to improve acceptability to beneficiaries. Specifically, for these settings, it will be important
to inform community members about IOT in a way that is
sensitive to existing beliefs, harnessing and encouraging
enabling attitudes (such as recognition of the danger of
excessive blood loss) and mitigating the impact of potential barriers (such as the traditional belief for the need of
postpartum blood loss). Identification of the MW as a key
advisor for health highlights that these providers would
likely be an effective channel through which this information could be delivered to the community.
Among healthcare providers, opinions about IOT were
predominantly positive, particularly in relation to ease of
use. However, remarks from healthcare providers were
often tempered with expressions of concern or apprehension. Given that IOT uses a different administration route, many providers expressed their desire to be
assured of its efficacy and safety. Robust evidence of safety
and efficacy will be generated as part of the regulatory
requirements for the product. Attitudes of healthcare
providers expressed in this study highlight the importance of making this data readily available to promote
acceptance.
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a MW was acceptable to most stakeholders, and the ease
of product use, heat stability and non-injectable delivery
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and mothers through participatory approaches starting
from the antenatal period will also enhance the operational feasibility of the IOT product into the community.
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